Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 5 (May)

1. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R).
   Age Ageing, 34(3): 268-73. [Abstract] [Full-text]
2. Dementia in Parkinson's disease: a post-mortem study in a population of brain donors.
   Int J Geriatr Psychiatry, 20(5): 418-22. [Abstract] [Full-text]
3. Is freezing of gait in Parkinson's disease related to asymmetric motor function?
   Ann Neurol, 57(5): 656-63. [Abstract] [Full-text]
4. Clinical features of LRRK2-associated Parkinson's disease in central Norway.
   Ann Neurol, 57(5): 762-5. [Abstract] [Full-text]
5. The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics.
   Neuroepidemiology, 24(3): 151-67. [Abstract] [Full-text]
6. Timing and direction selectivity of subthalamic and pallidal neurons in patients with Parkinson disease.
   Exp Brain Res, 162(4): 407-16. [Abstract] [Full-text]
7. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism.
   FEMS Immunol Med Microbiol, 44(2): 129-35. [Abstract] [Full-text]
8. Direction-specific postural instability in subjects with Parkinson's disease.
   Exp Neurol, 193(2): 504-21. [Abstract] [Full-text]
9. The beneficial effects of subthalamic nucleus stimulation on manipulative finger force control in Parkinson's disease.
   Exp Neurol, 193(2): 427-36. [Abstract] [Full-text]
10. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?
    Exp Neurol, 193(2): 279-90. [Abstract] [Full-text]
11. Reduced basal activity and increased functional homogeneity in sensorimotor and striatum of a Parkinson's disease rat model: a functional MRI study.
    Eur J Neurosci, 21(8): 2227-32. [Abstract] [Full-text]
12. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Mov Disord, 20(5): 523-39. [Abstract] [Full-text]
13. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
    Mov Disord, 20(5): 602-10. [Abstract] [Full-text]
14. Alpha-synuclein mRNA expression in sporadic Parkinson's disease.
    Mov Disord, 20(5): 620-3. [Abstract] [Full-text]
15. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
    Mov Disord, 20(5): 616-9. [Abstract] [Full-text]
16. Investigation of genes coding for inflammatory components in Parkinson's disease.
    Mov Disord, 20(5): 569-73. [Abstract] [Full-text]
17. Amygdalar and hippocampal MRI volumetric reductions in Parkinson's disease with dementia.
    Mov Disord, 20(5): 540-4. [Abstract] [Full-text]
18. FP-CIT and MIBG scintigraphy in early Parkinson's disease.
    Mov Disord, 20(5): 552-61. [Abstract] [Full-text]
19. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease?
    Acta Neurol Scand, 111(6): 353-9. [Abstract] [Full-text]
20. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients.
    Acta Neurol Scand, 111(6): 351-2. [Abstract] [Full-text]
21. Comparison of patients with Parkinson's disease or cerebellar lesions in the production of periodic movements involving event-based or emergent timing.
    Brain Cogn, 58(1): 84-93. [Abstract] [Full-text]
22. Variable foreperiod deficits in Parkinson's disease: dissociation across reflexive and voluntary behaviors.
    Brain Cogn, 58(1): 49-61. [Abstract] [Full-text]
23. Effects of internal clock and memory disorders on duration reproductions and duration productions in patients with Parkinson's disease.
    Brain Cogn, 58(1): 35-48. [Abstract] [Full-text]
24. Unilateral subthalamic nucleus deep brain stimulation contralateral to thalamic stimulation in Parkinson disease.
    Parkinsonism Relat Disord, 11(4): 257-8. [Abstract] [Full-text]
25. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
    Parkinsonism Relat Disord, 11(4): 253-6. [Abstract] [Full-text]
26. Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery.
    Parkinsonism Relat Disord, 11(4): 247-52. [Abstract] [Full-text]
27. Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features.
    Parkinsonism Relat Disord, 11(4): 227-32. [Abstract] [Full-text]
28. Quality of life in patients with Parkinson's disease.
    Parkinsonism Relat Disord, 11(4): 221-6. [Abstract] [Full-text]
29. Visual event-related potentials under different interstimulus intervals in Parkinson's disease: relation to motor disability, WAIS-R, and regional cerebral blood flow.
    Parkinsonism Relat Disord, 11(4): 209-19. [Abstract] [Full-text]
30. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.
    Brain Res Brain Res Protoc, 15(1): 46-51. [Abstract] [Full-text]
31. A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.
    Acta Psychiatr Scand, 111(6): 403-9. [Abstract] [Full-text]
32. UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study.
    Neurosci Lett, 381(1): 131-4. [Abstract] [Full-text]
33. Neuroinflammatory processes in Parkinson's disease.
    Parkinsonism Relat Disord, 11: S9-S15. [Abstract] [Full-text]
34. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?
    Parkinsonism Relat Disord, 11: S47-51. [Abstract] [Full-text]
35. Pathological substrate of dementia in Parkinson's disease--its relation to DLB and DLBD.
    Parkinsonism Relat Disord, 11: S41-5. [Abstract] [Full-text]
36. A definition of Parkinson's disease.
    Parkinsonism Relat Disord, 11: S39-40. [Abstract] [Full-text]
37. Controversy: is Parkinson's disease a single disease entity? Yes.
    Parkinsonism Relat Disord, 11: S31-7. [Abstract] [Full-text]
38. Pathogenesis of nigral cell death in Parkinson's disease.
    Parkinsonism Relat Disord, 11: S3-7. [Abstract] [Full-text]
39. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Parkinsonism Relat Disord, 11: S25-9. [Abstract] [Full-text]
40. The nature of the parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam and magnesium deficiency.
    Parkinsonism Relat Disord, 11: S17-23. [Abstract] [Full-text]
41. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder.
    Clin Neurol Neurosurg, 107(4): 306-9. [Abstract] [Full-text]
42. Treatment of motor dysfunction in Parkinson's disease: an overview.
    Clin Neurol Neurosurg, 107(4): 269-81. [Abstract] [Full-text]
43. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease.
    Antioxid Redox Signal, 7(5): 685-93. [Abstract] [Full-text]
44. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders.
    Antioxid Redox Signal, 7(5): 672-84. [Abstract] [Full-text]
45. Quantitative gait analysis in Parkinson's disease: comparison with a healthy control group.
    Arch Phys Med Rehabil, 86(5): 1007-13. [Abstract] [Full-text]
46. The effect of external rhythmic cues (auditory and visual) on walking during a functional task in homes of people with Parkinson's disease.
    Arch Phys Med Rehabil, 86(5): 999-1006. [Abstract] [Full-text]
47. Metaiodobenzylguanidine (MIBG) scintigraphy at various parts of the body in Parkinson's disease and multiple system atrophy.
    Auton Neurosci, 119(1): 56-60. [Abstract] [Full-text]
48. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.
    Neurosci Res, 52(2): 185-94. [Abstract] [Full-text]
49. Excessive daytime sleepiness in parkinsonism.
    Sleep Med Rev, 9(3): 185-200. [Abstract] [Full-text]
50. Genetic heterogeneity in rapid onset dystonia-parkinsonism: description of a new family.
    J Neurol Neurosurg Psychiatry, 76(6): 860-2. [Abstract] [Full-text]
51. Bilateral subthalamic nucleus stimulation improves balance control in Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 76(6): 780-7. [Abstract] [Full-text]
52. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?
    J Neurol Neurosurg Psychiatry, 76(6): 775-9. [Abstract] [Full-text]
53. Functional improvement after subthalamic stimulation in Parkinson's disease: a non-equivalent controlled study with 12-24 month follow up.
    J Neurol Neurosurg Psychiatry, 76(6): 769-74. [Abstract] [Full-text]
54. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease.
    Neurosci Lett, 381(3): 294-8. [Abstract] [Full-text]
55. The relationship between local field potential and neuronal discharge in the subthalamic nucleus of patients with Parkinson's disease.
    Exp Neurol, 194(1): 212-20. [Abstract] [Full-text]
56. Parkinsonian action tremor: interference with object manipulation and lacking levodopa response.
    Exp Neurol, 194(1): 151-60. [Abstract] [Full-text]
57. Cortico-cortical coupling in Parkinson's disease and its modulation by therapy.
    Brain, 128: 1277-91. [Abstract] [Full-text]
58. Saccadic eye movement changes in Parkinson's disease dementia and dementia with Lewy bodies.
    Brain, 128: 1267-76. [Abstract] [Full-text]
59. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.
    Brain, 128: 1314-22. [Abstract] [Full-text]
60. Rule-based category learning is impaired in patients with Parkinson's disease but not in patients with cerebellar disorders.
    J Cogn Neurosci, 17(5): 707-23. [Abstract] [Full-text]
61. Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease.
    Hum Genet, 117(1): 27-33. [Abstract] [Full-text]
62. Entacapone in the treatment of Parkinson's disease.
    Lancet Neurol, 4(6): 366-70. [Abstract] [Full-text]
63. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis.
    Lancet Neurol, 4(6): 362-5. [Abstract] [Full-text]
64. Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease.
    Neurosci Lett, 382(1): 191-4. [Abstract] [Full-text]
65. Frequency dependent effects of subthalamic nucleus stimulation in Parkinson's disease.
    Neurosci Lett, 382(1): 5-9. [Abstract] [Full-text]
66. Mitochondrial DNA haplogroup K is associated with a lower risk of Parkinson's disease in Italians.
    Eur J Hum Genet, 13(6): 748-52. [Abstract] [Full-text]
67. Differences in neuronal firing rates in pallidal and cerebellar receiving areas of thalamus in patients with Parkinson's disease, essential tremor, and pain.
    J Neurophysiol, 93(6): 3094-101. [Abstract] [Full-text]
68. Spontaneous pallidal neuronal activity in human dystonia: comparison with Parkinson's disease and normal macaque.
    J Neurophysiol, 93(6): 3165-76. [Abstract] [Full-text]
69. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
    J Neurosci Res, 80(5): 646-54. [Abstract] [Full-text]
70. Dementia, stroke and Parkinson's disease in Spanish populations: a review of door-to-door prevalence surveys.
    Neuroepidemiology, 24(4): 179-88. [Abstract] [Full-text]
71. Venous air embolism during deep brain stimulation surgery in an awake supine patient.
    Stereotact Funct Neurosurg, 83(1): 32-5. [Abstract] [Full-text]
72. Catechol-O-methyltransferase and monoamine oxidase B genes and susceptibility to sporadic Parkinson's disease in a Polish population.
    Eur Neurol, 53(2): 68-73. [Abstract] [Full-text]
73. Error analysis of MRI and leksell stereotactic frame target localization in deep brain stimulation surgery.
    Stereotact Funct Neurosurg, 83(1): 1-5. [Abstract] [Full-text]
74. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
    Neurobiol Aging, 26(8): 1183-92. [Abstract] [Full-text]
75. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.
    Eur J Nucl Med Mol Imaging, 32(6): 689-95. [Abstract] [Full-text]
76. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases.
    Med Hypotheses, 65(2): 353-62. [Abstract] [Full-text]
77. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Behav Brain Res, 162(1): 1-10. [Abstract] [Full-text]
78. Time-frequency analysis of transient neuromuscular events: dynamic changes in activity of the subthalamic nucleus and forearm muscles related to the intermittent resting tremor.
    J Neurosci Methods, 145(1): 151-8. [Abstract] [Full-text]
79. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases.
    Neurosci Lett, 382(3): 327-31. [Abstract] [Full-text]
80. LRRK2 R1441G in Spanish patients with Parkinson's disease.
    Neurosci Lett, 382(3): 309-11. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.